BHCM
IART icon

Brevan Howard Capital Management’s Integra LifeSciences IART Stock Holding History

Brevan Howard Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$474K Buy
50,317
+39,095
+348% +$429K ﹤0.01% 1330
2025
Q4 		$139K Sell
11,222
-32,166
-74% -$428K ﹤0.01% 1645
2025
Q3 		$622K Buy
+43,388
New +$594K ﹤0.01% 1171
2025
Q1 		– Sell
-10,279
Closed -$233K – 1295
2024
Q4 		$233K Sell
10,279
-3,953
-28% -$86.3K ﹤0.01% 861
2024
Q3 		$259K Buy
+14,232
New +$330K ﹤0.01% 913
2024
Q2 		– Sell
-6,287
Closed -$223K – 1199
2024
Q1 		$223K Buy
+6,287
New +$251K ﹤0.01% 762

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Brevan Howard Capital Management's IART Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Integra LifeSciences (IART) stake by 348% in Q1 2026, buying an estimated $429K and bringing the position to 50,317 shares worth $474K. The position accounts for ﹤0.01% of the portfolio, ranked #1330.

Brevan Howard Capital Management first reported a position in IART in Q1 2024 and has held it in 6 quarters since. The position peaked at $622K in Q3 2025. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • Brevan Howard Capital Management held 50,317 shares of Integra LifeSciences worth $474K as of Q1 2026.
  • Brevan Howard Capital Management bought 39,095 Integra LifeSciences shares in Q1 2026, an estimated $429K.
  • Integra LifeSciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1330 holding.
  • Brevan Howard Capital Management first reported a position in Integra LifeSciences in Q1 2024 and has held it in 6 quarters since.
  • Brevan Howard Capital Management's Integra LifeSciences position peaked at $622K in Q3 2025.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.